
What We’re Reading: Medicaid Expansion for Mental Health; CVD Surge by 2050; MDMA-Based Therapy for PTSD
Expansion of Medicaid coverage will now include all-in-one mental health and substance use clinics; 61% of adults are estimated to have cardiovascular disease (CVD) by 2050; the FDA has taken a historic step in potential psychedelic drug approval.
Medicaid Expanding Funding for Mental Health, Substance Use Clinics
HHS has announced that certified community behavioral health clinics (CCBHCs) in 10 additional states will now be eligible for Medicaid reimbursements,
American Heart Association Warns of Surge in CVD by 2050
New research from the American Heart Association has forecasted that 61% of US adults will have cardiovascular disease (CVD) by 2050, largely due to increasing cases of high blood pressure and an aging population,
FDA Panel to Review MDMA-Based Therapy for PTSD
An FDA advisory panel is set to discuss the potential approval of an MDMA (or ecstasy)-based therapy for post-traumatic stress disorder (PTSD), a significant milestone for psychedelic drug treatment,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.